Its not the drug Herceptin being tested, it is the delivery method DEP. The Herceptin by itself had poor results as did the Kadcyla and Saline. The model shows that when the Herceptin and DEP were added together where the DEP is the delivery vehicle, there was a significant improvement. Herceptin can kill the cancer efficiently if it is administered by the DEP technology.
Starpharma links with Syngenta, Novartis, Astrazenica, Adama, and Chemchina, page-25
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.010(9.09%) |
Mkt cap ! $50.17M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 12.0¢ | 11.0¢ | $127.2K | 1.070M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 130918 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 103000 | 3 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |